What is Madrigal Pharmaceuticals, Inc.'s 2029?

Madrigal Pharmaceuticals, Inc. (MDGL) reported 2029 of $29.98M in Q1 2026.

Madrigal Pharmaceuticals, Inc. MDGL 2029

2029 at other companies

Morgan StanleyMS

$115.47B+14.7%

JPMorgan ChaseJPM

$0-100%

PopularBPOP

——

PopularBPOP

——

PopularBPOP

——

PopularBPOP

——

Other financials

Income statement

See full

Revenue$311.3M+127%

Gross profit$43.5M—

Operating income-$92.7M-16.9%

Net income-$94.4M-28.9%

EPS (diluted)-$3.25-24.5%

Balance sheet

See full

Cash & equivalents$232.2M+23.1%

Total debt$377.3M+187%

Total equity$543.5M-23.5%

Total assets$1.2B+23.1%

Cash flow

See full

Operating cash flow-$167.4M-88.4%

CapEx$3.8M—

Free cash flow-$171.3M-92.7%

Valuation

See full

Market cap$11.66B+64.2%

Enterprise value$11.81B+67.5%

P/S10.3×-12.1×

Profitability

See full

Gross margin96.5%—

Operating margin-27.7%-12.2pp

Net margin-27.3%-12.0pp

FCF margin-59.8%-29.6pp

Returns & leverage

See full

Return on equity-49.3%-0.8pp

Debt / equity0.7×+0.5×

Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s 2029?: Madrigal Pharmaceuticals, Inc. (MDGL) reported 2029 of $29.98M in Q1 2026.